IPP Bureau
Cupid to set up FMCG manufacturing facility in Saudi Arabia
By IPP Bureau - December 30, 2025
The plant is expected to enhance regional supply capabilities
Astal signs LoI with Immuna Therapeutics
By IPP Bureau - December 30, 2025
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
By IPP Bureau - December 30, 2025
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
By IPP Bureau - December 30, 2025
The study met its primary endpoint with flying colors
Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
By IPP Bureau - December 30, 2025
The partnership also sets the stage for broader collaboration on rare disease treatments
Chennai's VS Hospitals introduce cutting-edge brain therapy with TMS
By IPP Bureau - December 30, 2025
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Next Gen Diagnostics to spin off infection prevention unit
By IPP Bureau - December 29, 2025
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
By IPP Bureau - December 29, 2025
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
By IPP Bureau - December 29, 2025
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure
By IPP Bureau - December 29, 2025
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
CPHI & PMEC India 2025 ignites pharma innovation and partnerships
By IPP Bureau - December 29, 2025
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
ENHERTU gains first-ever nod in China for metastatic breast cancer
By IPP Bureau - December 29, 2025
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe
By IPP Bureau - December 29, 2025
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Govt cancels registration of popular cosmetic product over misleading claims
By IPP Bureau - December 29, 2025
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
US House passes Bill reauthorizing FDA rare disease incentive program
By IPP Bureau - December 29, 2025
